Genmab A/S (LON:0MGB)
1,286.75
-7.20 (-0.56%)
At close: Apr 16, 2025
Genmab Revenue
In the year 2024, Genmab had annual revenue of 21.53B DKK with 30.67% growth. Genmab had revenue of 6.44B in the quarter ending December 31, 2024, with 35.34% growth.
Revenue
21.53B DKK
Revenue Growth
+30.67%
P/S Ratio
4.00
Revenue / Employee
8.03M DKK
Employees
2,682
Market Cap
9.55B GBP
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21.53B | 5.05B | 30.67% |
Dec 31, 2023 | 16.47B | 1.97B | 13.57% |
Dec 31, 2022 | 14.51B | 6.09B | 72.33% |
Dec 31, 2021 | 8.42B | -1.69B | -16.75% |
Dec 31, 2020 | 10.11B | 4.75B | 88.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
HSBC Holdings | 48.93B |
Shell | 227.10B |
Unilever | 50.25B |
Rio Tinto Group | 42.86B |
RELX PLC | 9.43B |
British American Tobacco p.l.c. | 25.87B |
Rolls-Royce Holdings | 18.91B |
Genmab News
- 9 days ago - Genmab's Outlook Beyond Darzalex's Patent Cliff - Seeking Alpha
- 9 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 - GlobeNewsWire
- 10 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 14 days ago - Genmab A/S Share Capital Reduction - GlobeNewsWire
- 17 days ago - Transactions In Connection with Share Buy-back Program - GlobeNewsWire
- 23 days ago - Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewsWire
- 23 days ago - Genmab drops as Bernstein cuts on Darzalex patent cliff - Seeking Alpha
- 24 days ago - TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - GlobeNewsWire